Necrobiosis lipoidica is an uncommon but distinctive inflammatory skin condition strongly associated with diabetes — affecting less than 1% of adults with diabetes. Lesions present as yellow-brown atrophic plaques (raised flat areas) typically on the front of the lower legs, with characteristic reddish borders and yellow-brown waxy centers that may show visible underlying blood vessels. The mechanism involves collagen degeneration and microvascular changes. Two-thirds of affected adults have diabetes (type 1 or type 2); one-third don’t and some develop diabetes later. The condition is more common in women (3:1 ratio). The main clinical concern is ulceration in 25-30% of cases — lesions break down through the thinned atrophic skin, creating chronic wounds that heal poorly. Treatment is challenging — no therapy fully resolves lesions, though topical and intralesional corticosteroids, topical tacrolimus, pentoxifylline, and other second-line options can reduce inflammation.
Clinical Presentation
- Yellow-brown waxy atrophic plaques, 1-10 cm in size.
- Reddish-purple raised borders.
- Yellow-brown central area, sometimes with visible underlying blood vessels (telangiectasias).
- Typically on shins (90% of cases); can occur on thighs, forearms, scalp.
- Usually bilateral and symmetric.
- Slow growth over months to years.
- Often asymptomatic; can be painful especially with ulceration.
- Can ulcerate in 25-30% of cases.
Diabetes Association
| Population | Necrobiosis lipoidica prevalence |
|---|---|
| General US adults | <0.1% |
| Type 1 diabetes | ~0.3-1% |
| Type 2 diabetes | ~0.3-0.5% |
| Women vs men | 3:1 female predominance |
| Among NL patients with diabetes | ~2/3 of all NL cases |
| NL patients without diabetes (some develop later) | ~1/3 of all NL cases |
Diagnosis
- Clinical exam is usually sufficient given characteristic appearance.
- Dermatoscopy may help.
- Biopsy if diagnosis uncertain — shows necrobiosis (collagen degeneration) and granulomatous inflammation.
- Differential: diabetic dermopathy (smaller, no ulceration), granuloma annulare (different pattern), morphea (more sclerotic).
- Test for diabetes if not previously diagnosed.
Treatment Options
- Topical corticosteroids: medium to high potency; reduce inflammation; can worsen atrophy with long-term use.
- Intralesional corticosteroids: injected into active border; can cause atrophy.
- Topical tacrolimus (Protopic): immunomodulator; no atrophy risk.
- Pentoxifylline: improves blood flow; oral medication.
- Antiplatelet therapy: aspirin, dipyridamole.
- Phototherapy (PUVA, UVA1): for refractory cases.
- Systemic immunosuppressants: methotrexate, biologics for severe cases.
- Hyperbaric oxygen therapy: for ulcerated lesions.
- Wound care: essential for ulcerated lesions.
The Ulceration Problem
- 25-30% of NL lesions ulcerate.
- Adults with diabetes have impaired wound healing.
- Ulcers can be chronic — months to years.
- Infection risk including cellulitis and osteomyelitis.
- Standard wound care: cleaning, dressing changes, debridement if needed.
- Hyperbaric oxygen therapy has some evidence for chronic NL ulcers.
- Plastic surgery referral for some refractory cases.
Prevention and Monitoring
- Glucose control may reduce new lesion formation.
- Trauma to existing lesions can trigger ulceration — protect with padding when possible.
- Avoid tight clothing rubbing on lesions.
- Sun protection for affected areas.
- Regular dermatologist follow-up every 6-12 months.
- Document changes with photos.
- Annual eye and kidney screening (microvascular disease association).
The Bottom Line
Necrobiosis lipoidica is an uncommon but distinctive inflammatory skin condition strongly associated with diabetes — affecting less than 1% of adults with diabetes. Lesions present as yellow-brown atrophic plaques with reddish borders typically on the shins, often showing visible underlying blood vessels. The condition is more common in women (3:1) and two-thirds of affected adults have diabetes. The main clinical concern is ulceration in 25-30% of cases — lesions break down through thinned atrophic skin creating chronic wounds that heal poorly in adults with diabetes. Treatment is challenging — no therapy fully resolves lesions. First-line topical or intralesional corticosteroids reduce inflammation but can worsen atrophy with long use. Second-line options include topical tacrolimus (no atrophy risk), pentoxifylline, antiplatelet therapy, and for refractory cases phototherapy or systemic immunosuppressants. Ulcerated lesions require wound care and may benefit from hyperbaric oxygen therapy. Glucose control may slow new lesion formation but won’t reverse existing lesions. Trauma protection prevents ulceration. For adults with NL and diabetes, regular dermatologist follow-up every 6-12 months is reasonable, along with continued monitoring for microvascular complications (retinopathy, nephropathy). See our broader diabetic dermopathy guide for context on the more common diabetic skin condition.
